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infection control & hospital epidemiology

original article

The Effect of Adding Comorbidities to Current Centers for Disease
Control and Prevention Central-Line–Associated Bloodstream
Infection Risk-Adjustment Methodology
Sarah S. Jackson, MPH;1 Surbhi Leekha, MBBS, MPH;1 Laurence S. Magder, PhD;1 Lisa Pineles, MA;1
Deverick J. Anderson, MD, MPH;2 William E. Trick, MD;3 Keith F. Woeltje, MD, PhD;4 Keith S. Kaye, MD, MPH;5
Kristen Stafford, PhD, MPH;1 Kerri Thom, MD, MS;1 Timothy J. Lowe, PhD;6 Anthony D. Harris, MD, MPH1

background. Risk adjustment is needed to fairly compare central-line–associated bloodstream infection (CLABSI) rates between hospitals.
Until 2017, the Centers for Disease Control and Prevention (CDC) methodology adjusted CLABSI rates only by type of intensive care unit
(ICU). The 2017 CDC models also adjust for hospital size and medical school afﬁliation. We hypothesized that risk adjustment would be
improved by including patient demographics and comorbidities from electronically available hospital discharge codes.
methods. Using a cohort design across 22 hospitals, we analyzed data from ICU patients admitted between January 2012 and December
2013. Demographics and International Classiﬁcation of Diseases, Ninth Edition, Clinical Modiﬁcation (ICD-9-CM) discharge codes were obtained
for each patient, and CLABSIs were identiﬁed by trained infection preventionists. Models adjusting only for ICU type and for ICU type plus
patient case mix were built and compared using discrimination and standardized infection ratio (SIR). Hospitals were ranked by SIR for each
model to examine and compare the changes in rank.
results. Overall, 85,849 ICU patients were analyzed and 162 (0.2%) developed CLABSI. The signiﬁcant variables added to the ICU model
were coagulopathy, paralysis, renal failure, malnutrition, and age. The C statistics were 0.55 (95% CI, 0.51–0.59) for the ICU-type model and
0.64 (95% CI, 0.60–0.69) for the ICU-type plus patient case-mix model. When the hospitals were ranked by adjusted SIRs, 10 hospitals (45%)
changed rank when comorbidity was added to the ICU-type model.
conclusions. Our risk-adjustment model for CLABSI using electronically available comorbidities demonstrated better discrimination than
did the CDC model. The CDC should strongly consider comorbidity-based risk adjustment to more accurately compare CLABSI rates across
hospitals.
Infect Control Hosp Epidemiol 20 1 7; 1– 6

Central-line–associated bloodstream infections (CLABSIs) are
responsible for substantial morbidity and mortality among
hospitalized patients. Patients with CLABSIs are at a higher risk of
death, have longer hospital stays, and incur more healthcare costs
than patients without CLABSIs.1 Since January 2012, hospital
reimbursement by the Centers for Medicare and Medicaid
Services (CMS) has depended on public reporting of CLABSI
rates. CMS hospitals use the operational system of the Centers for
Disease Control and Prevention (CDC) National Healthcare
Safety Network (NHSN) to facilitate reporting.2
The CDC uses risk adjustment to more fairly compare CLABSI
rates across hospitals. Until 2017, the CDC NSHN adjusted
CLABSI rates only by type of intensive care unit (ICU). In 2017,

the CDC added hospital size (ie, number of licensed beds) and
medical school afﬁliation as additional risk-adjustment variables.3
However, neither of these CDC models adjust for individual
patient level factors, including comorbid conditions. We
hypothesized that risk adjustment could be improved by including demographics and comorbid conditions from electronically
available hospital discharge codes.

methods
Using a cohort design, we retrospectively analyzed ICU
patients admitted between January 1, 2012, and December 31,
2013, to 22 US hospitals. Facilities were recruited as part of a
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partnership between Premier, Inc, the Society for Healthcare
Epidemiology of America (SHEA) Research Network, and
the University of Maryland School of Medicine. Institutional
review board and facility consent were obtained from facilities
that voluntarily participated in the study.
Using Premier’s Quality Advisor database, we obtained
demographic and International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation (ICD-9-CM) discharge codes for
each adult ICU patient. Patients with CLABSIs were identiﬁed
by trained infection preventionists at each hospital using CDC
NHSN deﬁnitions.4 We also obtained information on the size
of the hospital (ie, number of beds) and whether the hospital
was associated with an academic medical school.
Risk-adjustment models were built using discrete survival
analysis, a method that accounts for time at risk.5 Speciﬁcally,
acquisition of CLABSI on each day in the ICU was used as the
outcome of a binary regression model with a complementary
log-log link. A random intercept for hospital was included in
the model to account for the clustering of patients within
hospitals.
We constructed 2 models: (1) a model containing only ICUtype (ie, CDC methodology prior to 2017) and (2) a model
containing ICU-type plus patient case-mix variables. For the
latter model, we identiﬁed candidate comorbidity variables using
expert consensus, which has been reported elsewhere.6 Using a
modiﬁed Delphi method, 9 infectious disease and infection
control experts were asked to rate the 35 comorbid conditions
found in the Charlson and Elixhauser comorbidity indices from
1 (not at all related) to 5 (strongly related), based on perceived
relatedness to CLABSI. These experts rated the following 14
conditions in terms of causality with CLABSI as 3 (somewhat
related) or higher: coagulopathy, dementia, diabetes without
complications, diabetes with complications, drug abuse,
hemiplegia or paraplegia, HIV/AIDS, lymphoma, malignancy,
solid tumor with metastasis, severe liver disease, obesity, renal
disease, and weight loss (malnutrition). These 14 conditions
(identiﬁed using ICD-9-CM codes), along with ICU type, age,
gender, race, hospital size, and medical school afﬁliation
were entered into the model as potential predictors of CLABSI.
Hospital size was deﬁned in the 2017 CDC NHSN model as a
binary variable indicating that the number of beds in the hospital
was ≥276.3 Variables were retained using backward selection if
they met the signiﬁcance level of α < 0.05.
For both models, we estimated the marginal predicted
probabilities of a CLABSI for each patient day in the ICU
without including the random effect in the prediction so that
hospital characteristics did not inﬂuence these values. These
predicted probabilities were then used to generate the C
statistic and 95% conﬁdence interval (CI) for both models.
The C statistic is a measure of discrimination, or the model’s
ability to discriminate between those with and without
the outcome. The C statistic is the chance that the model
will assign a higher probability to patients with CLABSIs
than without.7 Values for the C statistic range from 0.50, a
probability no different from chance, to 1.0, which is perfect

prediction. Calibration, the model’s ability to accurately
quantify the probability of the outcome, was assessed with a
calibration plot. The predicted probabilities were plotted
against the observed proportion of CLABSI in deciles, and a
45° line was added to visually inspect how well the model was
calibrated. In a perfectly calibrated model, the points would
rest exactly on the 45° line, implying that the predicted risks
are equal to the observed rate.8,9
Unadjusted CLABSI rates were calculated for each hospital by
dividing the number of CLABSIs by the total number of ICU
days. To calculate risk-adjusted rates, the predicted probabilities
from the risk-adjustment model were summed to estimate the
expected number of CLABSI events for each hospital. Standardized infection ratios (SIR) for each hospital were calculated by
dividing the observed number of CLABSI by the expected
number predicted by the ICU-type plus patient case-mix model.
An SIR above 1 indicated that the hospital reported a greater
number of CLABSIs than expected, while an SIR below 1
indicated that the hospital reported a lower number of CLABSIs
than expected by the model.10 Hospitals were then ranked by the
case-mix risk-adjusted SIRs and compared to the rankings when
ordered by the ICU-type–only risk-adjusted SIRs.
All analyses were conducted using SAS version 9.4 software
(SAS Institute, Cary, NC). The calibration plots were generated using the “ggplot2” package in R studio version 0.99.902
software (R Foundation for Statistical Computing, Vienna,
Austria).

resul ts
In total, 22 hospitals contributed ICU data. The analysis included
85,849 ICU patients, of whom 162 (0.2%) developed CLABSIs.
Of the 22 hospitals, 16 (73%) were large (≥296 beds), 11 (50%)
were afﬁliated with medical schools, and 20 (90%) were located
in urban areas. Across hospitals, 22,560 (26%) patients were
from 9 medical cardiac critical care units, 18,157 (21%) were
from 8 medical critical care units, 34,537 (40%) were from 14
medical/surgical critical care units, and 10,595 (12%) were from
6 surgical critical care units based on CDC ICU deﬁnitions. All
patients had a minimum of 9 ICD-9-CM codes, with a median of
27 and a maximum of 65 codes.
Table 1 presents a bivariate analysis of the relationship
between CLABSI and patient demographics and comorbidities.
Intensive care unit type, age, coagulopathy, paralysis, liver
disease, renal failure, and malnutrition were signiﬁcant at the
P < .10 level in the bivariate analysis. Using the medical cardiac
care ICU as the reference category, medical/surgical critical care
ICU (P = .06) and surgical critical care ICU (P = .03) were
predictive of CLABSI, but the medical critical care ICU (P = .40)
was not. Table 2 presents the results of the ICU-type plus patient
case-mix model. The following variables were added to the ICUtype–only model: coagulopathy (P = .01), paralysis (P = .03),
renal failure (P < .01), malnutrition (P < .01), and patient
age in 10-year increments (P < .01). Facility hospital size
(P = .33) and medical school afﬁliation (P = .152) were not
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table 1. Characteristics of 85,849 Patients With and Without Central-Line–Associated Bloodstream Infection
(CLABSI) Admitted to the Intensive Care Unit Between January 1, 2012, and December 31, 2013
Variable

CLABSI
(n = 162), n (%)

Non-CLABSI
(n = 85,687), n (%)

Hazard Ratio
(95% CI)

60.2 (17.2)
71 (0.17)
91 (0.18)

63.0 (16.9)
39,094 (99.8)
46,590 (99.8)

0.99 (0.98–1.00)
Reference
0.96 (0.70–1.31)

.012
.793

42 (0.29)
17 (0.17)
103 (0.15)

13,225 (99.7)
6,998 (99.8)
65,364 (99.8)

1.70 (1.15–2.52)
1.44 (0.85–2.42)
Reference

.008
.175

36 (0.14)
32 (0.16)
64 (0.18)
30 (0.24)
52 (0.39)
2 (0.24)
39 (0.15)
17 (0.23)
9 (0.15)
17 (0.45)
2 (0.45)
4 (0.34)
9 (0.11)
10 (0.24)
31 (0.37)
32 (0.20)
56 (0.28)
55 (0.47)

22,524 (99.8)
18,125 (99.8)
34,473 (99.8)
10,565 (99.7)
12,258 (99.6)
751 (99.7)
23,236 (99.8)
6,696 (99.8)
5,726 (99.8)
3,659 (99.5)
411 (99.5)
1,057 (99.6)
6,773 (99.9)
3,538 (99.7)
7,667 (99.6)
14,956 (99.8)
19,822 (99.7)
10,804 (99.5)

Reference
1.52 (0.85–2.70)
1.82 (1.03–3.22)
1.98 1.14 (3.46)
1.70 (1.22–2.37)
1.36 (0.34–5.12)
0.87 (0.61–1.26)
1.22 (0.74–2.01)
0.79 (0.40–1.55)
1.89 (1.14–3.14)
1.58 (0.39, 6.40)
1.60 (0.59–4.31)
0.63 (0.32–1.24)
1.42 (0.75–2.70)
1.68 (1.13–2.49)
1.02 (0.69–1.50)
1.38 (1.00–1.92)
1.74 (1.25–2.42)

Age, y, mean (SD)
Female
Male
Race
Black
Other
White
ICU type
Medical cardiac
Medical critical care
Medical/surgical critical care
Surgical critical care
Coagulopathy
Dementia
Diabetes uncomplicated
Diabetes complicated
Drug abuse
Paralysis
HIV/AIDS
Lymphoma
Malignancy
Metastatic cancer
Liver disease
Obesity
Renal disease
Weight loss (malnutrition)
NOTE.

P Value

.156
.040
.016
.002
.665
.468
.446
.489
.013
.524
.355
.185
.281
.010
.927
.050
.001

HIV/AIDS, human immunodeﬁciency virus/acquired immune deﬁciency syndrome.

table 2. Hazard Ratios, P Values, and the C Statistic for the ICU-Type Plus Patient CaseMix Model
Variable
ICU type
Medical cardiac
Medical critical care
Medical/surgical critical care
Surgical
Coagulopathy
No
Yes
Paralysis
No
Yes
Renal disease
No
Yes
Weight loss
No
Yes
Age per 10-year increase
NOTE.

HR (95% CI)

P Value

C Statistic (95% CI)
0.64 (0.60–0.69)

Reference
1.28 (0.72, 2.26)
1.70 (0.98, 2.95)
1.83 (1.04–3.20)

.400
.060
.034
.004

Reference
1.65 (1.17–2.30)
.029
Reference
1.76 (1.06–2.93)
.007
Reference
1.59 (1.13–2.22)
.010
Reference
1.56 (1.12–2.19)
0.88 (0.80–0.96)

.006

CI, conﬁdence interval.
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signiﬁcant predictors of CLABSI and were therefore dropped
from both models.
The C statistics were 0.55 (95% CI, 0.51–0.59) for the ICUtype–only model and 0.64 (95% CI, 0.60–0.69) for the ICU-type
plus patient case-mix model, with a statistically signiﬁcant
difference (P < .001) (Figure 1). When the hospitals were
ranked by adjusted SIRs and compared (Table 3), 10 hospitals
(45%) changed rank (4 increased in rank and 6 decreased in
rank) when comorbidities were added to the ICU-type–only
model. Figures 2 and 3 show the calibration of the ICUtype–only model and the ICU-type plus patient case-mix model.
Our ﬁnal model shows better calibration than the ICUtype–only model, which overestimated the expected rate relative
to the observed CLABSI rate in some subgroups.

d is c u s s i o n

ﬁgure 1. Receiver operating characteristic (ROC) curves
comparing the intensive care unit (ICU)-type–only model to the
ICU-type plus patient case-mix model.

In this retrospective cohort study, we have illustrated the importance of adjusting for patient case-mix variables including
comorbid conditions when comparing CLABSI rates across
hospitals. Other than the existing CDC model, this analysis is
the ﬁrst in developing risk-adjustment models for CLABSI.
Furthermore, the CDC models do not incorporate comorbid
conditions or other signiﬁcant patient factors such as age.
Although our model incorporating these factors showed modest
discrimination, it showed better discrimination than a model

table 3. Ranking of Hospitalsa With the Intensive Care Unit (ICU)-Type–Only Model and ICU-Type Plus Patient
Case-Mix Risk Adjustment
Hospital
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V

ICU-Type–Only
Model SIR

ICU-Type–Only
Model Rank

ICU-Type + CaseMix Model SIR

ICU-Type–Only +
Case-Mix Rank

Difference
in Rank

0.15
0.17
0.20
0.38
0.62
0.68
0.83
0.88
1.03
0.93
1.06
1.10
1.53
1.30
1.34
1.36
1.61
1.48
1.35
2.94
3.32
3.29

1
2
3
4
5
6
7
8
10
9
11
12
18
13
14
16
19
17
15
20
22
21

0.15
0.17
0.23
0.44
0.67
0.70
0.83
0.87
0.94
0.95
1.00
1.16
1.29
1.30
1.30
1.37
1.38
1.44
1.50
2.66
2.73
3.50

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

0
0
0
0
0
0
0
0
1
−1
0
0
5
−1
−1
0
2
−1
−4
0
1
−1

Direction

↓
↑
↓
↓
↑
↓
↓
↓
↑
↓

NOTE.
a

SIR, standardized infection ratio.
In order of ICU-type-only model ranking.
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ﬁgure 2. Calibration curve for the intensive care unit (ICU)type–only model.

ﬁgure 3. Calibration curve for the intensive care unit (ICU)type plus patient case-mix model.

using only ICU type (CDC risk model until 2017). The additional
2017 CDC variables of medical school afﬁliation and facility
hospital size were not statistically signiﬁcant predictors of CLABSI
in our cohort.
We have further demonstrated the importance of risk
adjustment by showing the change in rankings of the hospitals
that resulted when the risk adjustment model including
comorbid conditions was applied. Hospitals with a large
burden of patients with more comorbid conditions are
expected to have larger CLABSI rates, and their rankings will
improve once the risk adjustment model is applied. Likewise,
hospitals that serve healthier patients with fewer comorbidities

5

may decline in their performance rankings when SIRs are
adjusted for patient case mix. These shifts may have consequences regarding payments and penalties for individual
hospitals when all US hospitals are included in this ranking, as
is currently done by the CMS.
The CDC models prior to 2017 only adjusted for type of
ICU.10 The new 2017 CDC model added medical school
afﬁliation and facility hospital size as variables.3 Although these
variables are unlikely causally related to CLABSI occurrence,
they were probably selected as proxy variables for patient case
mix. However, while medical school afﬁliation may represent a
case mix of patients who have more comorbid conditions and
higher severity of illness that merits risk adjustment, it may also
represent more inexperienced providers that should not be
adjusted for when the intent is to use those adjusted rates for
quality-of-care comparisons. Similarly, facility hospital size is
likely associated with several patient case-mix and care delivery
factors, which make the direction of inﬂuence on CLABSI
difﬁcult to predict. Indeed, in our large and diverse cohort,
neither medical school afﬁliation nor facility hospital size were
signiﬁcantly associated with CLABSI. Therefore, we suggest that
it is better to directly adjust for patient demographics and
comorbid conditions when possible.
Our analysis has several strengths. Infection preventionists
used standardized CDC NHSN criteria to identify CLABSI
such that outcome assessment is comparable across hospitals.
We used comorbid conditions from discharge codes already
collected routinely for other purposes; therefore, the incorporation of these variables into current national risk adjustment
would not require any additional data collection burden on
the part of hospitals. In fact, ICD diagnostic codes are already
routinely transmitted to CMS by hospitals. The use of discharge
codes may also encourage the use of risk adjustment because
ICD diagnostic codes are easier to access and are collected on
every patient by trained individuals in a standardized fashion.
Our approach has some limitations. Most of our sample
consisted of large, urban facilities, which may limit the
generalizability of our ﬁndings to other hospitals. The Premier
database did not have data on central-line days, so we were unable
to use this measure for our denominator or to account for
patients with >1 line. Our use of ICU days as the denominator
may have underestimated the overall CLABSI rate in each unit,
which may have misclassiﬁed patient time at risk, but we have no
reason to believe that this misclassiﬁcation is differential. Work by
Horstman et al11 has shown that ICU days correlate strongly with
device days and that hospital performance rankings using either
measure are also strongly correlated. A criticism of the use of
ICD-9-CM codes in research is that they fail to capture all
patient comorbidities and could reﬂect codes that maximize
reimbursement.12,13 Research comparing the Charlson and
Elixhauser comorbidity indices derived from ICD-9-CM codes to
those same scores extracted from chart review revealed that the
sensitivity of the individual components varies greatly but that
speciﬁcity is nearly 100%.14,15 Therefore, while some patient
comorbidities may have been missed due to low sensitivity of the
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ICD codes, a condition assigned to a patient is likely to be
correct.14–16 Therefore, we may have underestimated the prevalence of these conditions in our study, resulting in smaller rank
changes after adjustment. Despite this limitation, our models still
demonstrated good discrimination. Another limitation is that we
used ICD-9-CM codes and hospitals have recently switched to
ICD-10 codes; however, this change is unlikely to affect the
discrimination of our model because the identiﬁed comorbid
conditions can be directly compared between ICD-9-CM and
ICD-10.17
Our analyses demonstrate the importance of using individual demographic data and comorbidities in risk-adjustment
models. We believe that the CDC and CMS should strongly
consider incorporating comorbid conditions obtained by
electronically available ICD codes into their risk adjustment
models for CLABSI.
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